Encouraging findings with immunotherapy aiming at ART-free virological control A significant step towards functional cure of HIV infection

HONG KONG SAR - Media OutReach Newswire – 12 November 2024 - Immuno Cure BioTech ("Immuno Cure"), a clinical-stage biotechnology group based in Hong Kong Science Park, is pleased to announce the completion of a first-in-human novel therapeutic HIV vaccine, ICVAX, Phase I clinical trial with encouraging findings of exceptional safety and promising immunogenicity profiles.